Academia / Nonprofits / Government agencies always get a discounted rate, as do companies that let us profile their population healthcare databases/registries in our resource. In addition, if you sign up for Unlimited Users worldwide for 2 or more years, you can receive a 10% discount (pre-paid)! Finally, licensing our B.R.I.D.G.E.
With registrations starting back in 1948, the National Cancer Registration and Analysis Service (NCRAS) is run by the National Disease Registration Service (NDRS) which is part of NHS England. It is responsible for cancer registration in England to support cancer epidemiology, public health, service monitoring and research. NCRAS is responsible for systematic collection of data about cancer and tumour diseases in England.
Sarah Stevens
Associate Director for NDRS
(National Disease Registration Service)
Email: sarah.stevens1@nhs.net
If you cannot reach the database manager, you may contact the organization by completing the contact form at:
https://digital.nhs.uk/ndrs/ndrs-contact-page
1. Webster L, Lawton S, Thackray K, Barclay M, Bomb M, Lyratzopoulos G, Dodwell D, Kipps E. The impact of the COVID-19 pandemic on the use of systemic therapy for patients diagnosed with cancer in England: A population-based study with a focus on breast and lung cancer. Cancer Epidemiology. 2025 Jun 1;96:102806.
2. Abiodun AT, Ju C, Welch CA, Lai J, Tyrer F, Chambers P, Paley L, Vernon S; NICOR Collaborative; Deanfield J, de Belder M, Rutherford MJ, Lambert PC, Slater S, Shiu KK, Wei L, Peake MD, Adlam D, Manisty C. Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer. JACC CardioOncol. 2025 Jun;7(4):345-356.
3. Roberts K, Cooper N, Webster L, Sharpless B, Round T, Gildea C, Nicholson BD. Characterising the volume and variation of multiple urgent suspected cancer referrals in England, April 2013–March 2018: a national cohort study. BMJ open. 2025 Apr 1;15(4):e097180.
4. Swanton C, Bachtiar V, Mathews C, Brentnall AR, Lowenhoff I, Waller J, Bomb M, McPhail S, Pinches H, Smittenaar R, Hiom S. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clinical Trials. 2025 Apr;22(2):227-38.
5. Trama A, Geerdes EE, Demuru E, De Angelis R, Karim-Kos HE, Troussard X, Bennett D, Marcos-Gragera R, Kuehni CE, Liu H, Bernasconi A. Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: results from EUROCARE-6, a population-based study. European Journal of Cancer. 2025 Mar 1:115336.
6. Di Carlo V, Eberle A, Stiller C, Bennett D, Katalinic A, Marcos-Gragera R, Girardi F, Larønningen S, Schultz A, Lima CA, Coleman MP. Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries. European Journal of Cancer. 2025 Feb 25;217:115213.
7. Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, Loong L, Walburga Y, Morris E, Hardy S, Torr B. Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer. BMJ oncology. 2025 Feb 25;4(1):e000574.
8. Botta L, Didonè F, Lopez-Cortes A, Nieto AC, Desandes E, Hjalgrim LL, Jakab Z, Stiller CA, Zeller B, Gatta G, Pritchard-Jones K. International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study. The Lancet Child & Adolescent Health. 2025 Feb 1;9(2):89-99.
9. Falcaro M, Castañón A, Ndlela B, Sasieni P. Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006–2020: a population-based trends analysis. The Lancet Regional Health–Europe. 2025 Feb 1;49.
10. Mumford L, Hogg R, Taylor A, Lanyon P, Bythell M, McPhail S, Chilcot J, Powter G, Cooke GS, Ward H, Thomas H. Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study. The Lancet. 2025 Jan 25;405(10475):314-28.
With data starting in 2003, the National Ambulatory Care Reporting System (NACRS) provides valuable insights into emergency department (ED) visits and lengths of stay reported by participating provinces and territories in Canada. NACRS collects demographic, administrative, clinical and service-specific data for ED, day surgery and other ambulatory care visits.
Email: help@cihi.ca
Phone: +1 613-241-5543
1. CIHI publishes a wealth of publicly available statistics (see https://www.cihi.ca/en/access-data-and-reports).
2. If you’re looking for more detailed information, you can make a custom data request by using their Data Inquiry Form at https://www.cihi.ca/en/data-inquiry-form.
1. Burgesson B, Lethbridge L, Haase D, Dunbar M; Published in collaboration with the Health Association of African Canadians. Disparities in Utilization Rates of Total Knee and Hip Arthroplasty Among Racially Visible Populations in Canada: A Retrospective Cohort Analysis. J Arthroplasty. 2025 Apr 11:S0883-5403(25)00336-5.
2. Dick K, Kaczmarek E, Ducharme R, Bowie AC, Dingwall-Harvey ALJ, Howley H, Hawken S, Walker MC, Armour CM. Transformer-based deep learning ensemble framework predicts autism spectrum disorder using health administrative and birth registry data. Sci Rep. 2025 Apr 7;15(1):11816.
3. Yin CY, Scott MM, Talarico R, Hakimjavadi R, Kierulf J, Webber C, Hawken S, Moledina A, Manuel D, Hsu A, Tanuseputro P, Fung C, Kaasalainen S, Molnar F, Shamon S, McIsaac DI, Kobewka D. Transfer from long-term care to acute care and risk of new permanent cognitive or physical disability among long-term care residents in Canada: protocol for a retrospective cohort study. BMJ Open. 2025 Jan 20;15(1):e086932.
4. Yao X, Champagne AS, McFaull SR, Thompson W. Temporal trends and characteristics of fall-related deaths, hospitalizations and emergency department visits among older adults in Canada. Health Promot Chronic Dis Prev Can. 2024 Nov;44(11-12):482-487.
5. Mirzadeh P, Kuk JL, Wharton S, Reid RA, Ardern CI. Healthcare outcomes and dispositions in persons with obesity within emergency departments in Ontario, Canada: A cross-sectional analysis of the National Ambulatory Care Reporting System (NACRS), 2018-2022. PLoS One. 2024 Sep 26;19(9):e0311190.
6. Khalid A, Muchaal PK, Julien DA. Human echinococcosis incidence in Canada: A retrospective descriptive study using administrative hospital and ambulatory visit data, 2000-2020. Can Commun Dis Rep. 2024 Sep 5;50(9):305-311.
7. Dengler J, Perlman M, Jennett M, Marcon E, Guilcher S. An Examination of Utilization Rates Over Time of Nerve and Tendon Transfers in Canada to Improve Upper Limb Function in Cervical Spinal Cord Injury. Plast Surg (Oakv). 2024 Aug;32(3):367-373.
8. Brissette V, Kapral MK, Yu B, Fang J, Odugbemi T, Shamy M, Fahed R, Dowlatshahi D, Gocan S, Martineau I. Seasonal Variations in Stroke Occurrence. Neuroepidemiology. 2024 Jul 22:1-10.
9. Ferro MA, Chan CKY, Browne DT, Colman I, Dubin JA, Duncan L. Suicidal Ideation and Attempts Among Youth With Physical-Mental Comorbidity in Canada: Proposal for an Epidemiological Study. JMIR Res Protoc. 2024 Jul 4;13:e57103.
10. Benny C, Hobin E, Andreacchi AT, Schwartz N, Smith BT. Socio-economic inequities in emergency department visits for wholly alcohol-attributable acute and chronic harms in Canada, 2003-2017. Drug Alcohol Rev. 2024 May;43(4):927-936.
The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a national register of all patients receiving biologic therapy for the treatment of psoriasis in the United Kingdom. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for Psoriasis should be registered in BADBIR. BADBIR has grown to be the largest psoriasis study of its kind globally.
BADBIR
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Email: badbir@manchester.ac.uk
Main Office Phone: +44 0161 306 1896
Patient and training enquiries: +44 0161 306 1908
Pharmacovigilance query: +44 0161 306 1911
If you are interested in using BADBIR data as a researcher, please email Joy Read (Research Coordinator) to describe your data request.
Email: research@bad.org.uk
1. Yiu ZZN, Smith CH, Laws P, Hampton PJ, Griffiths CEM, Warren RB; BADBIR Study Group; BSTOP Study Group. Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. JAMA Dermatol. 2025 Jul 1;161(7):731-738.
2. Phan DB, Lunt M, Warren RB, Yiu ZZN. Switching back to originator adalimumab from biosimilars in psoriasis: A cohort study from BADBIR. J Eur Acad Dermatol Venereol. 2025 Jul;39(7):e621-e624.
3. Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB; BADBIR Study Group. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025 May 29. doi: 10.1111/jdv.20739. Epub ahead of print.
4. Alabas OA, Evans I, Mcelhone K, Yiu ZZN, Reynolds NJ, Laws PM, Bewley A, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Cohort. Clin Exp Dermatol. 2025 May 22:llaf224. doi: 10.1093/ced/llaf224. Epub ahead of print.
5. Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Griffiths CEM; BADBIR study group. Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2025 Apr 28;192(5):907-916.
6. Phan DB, Bewley AP, Laws P, Mackenzie T, Smith CH, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN. Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. JAMA Dermatol. 2025 Apr 1;161(4):358-366.
7. Williams K, Lada G, Reynolds NJ, Mcelhone K, Evans I, Warren RB, Walton S, Hughes O, Bewley A, Mason K, Kleyn CE. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Clin Exp Dermatol. 2025 Mar 26;50(4):804-811.
8. Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, Yiu ZZN. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. Br J Dermatol. 2025 Mar 18;192(4):641-652.
9. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CE. The association of age at psoriasis onset and HLA-C* 06: 02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2024 May;190(5):689-700.
10. Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JN, Yiu ZZ, Smith CH, Griffiths CE. Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study. British Journal of Dermatology. 2024 Mar;190(3):441-4.
